Estrogen Stimulates Adenosine Receptor Expression Subtypes in Human Breast Cancer MCF-7 Cell Line

Overview

Journal Res Pharm Sci

Specialty Chemistry

Date 2018 Feb 2

PMID 29387112

Citations 14

Authors

Azam Mohamadi

Mahmoud Aghaei

Mojtaba Panjehpour

Affiliations

Soon will be listed here.

Abstract

Estrogen is a steroid hormone that plays a key role in the development and regulation of reproductive system. It has been shown that estrogen is related to breast cancer development through binding to its receptors. In order to uncover the estrogen effects on adenosine receptor expression, estrogen-positive MCF-7 cells were used to treat with agonist and antagonist of estrogen and then the mRNA expression of adenosine receptor subtypes were evaluated. Estrogen-positive MCF-7 cells were treated with various concentrations of 17β estradiol (E2) as an estrogen agonist, and ICI 182,780 as an estrogen antagonist. The gene expression of adenosine receptor subtypes were detected by real time RT-PCR. The results of MTT assay showed that E2 increased cell viability in a dose dependent manner. The expression pattern of all adenosine receptor subtypes are as follow; A2b > A1 > A2a > A3 in untreated MCF-7 cells. Obtained results showed that E2 incubation at 0.001-0.01 μM led to up-regulation of A1ARs, A2aARs and A3ARs dose dependently. E2 at 0.001 μM also had no significant effect on A2bARs expression but, at higher doses induced a considerable decrease in mRNA A2bARs expression. Treatment with antagonist confirmed that up-regulation of these receptors is mediated by estrogen receptor. Taken together, our results indicate that treatment of MCF-7 cells with E2 led to up-regulation of adenosine receptors. However, these effects were partially restored by treatment with antagonist suggesting that such effects are mediated by estrogen receptors.

Citing Articles

Chronic Caffeine Consumption, Alone or Combined with Agomelatine or Quetiapine, Reduces the Maximum EEG Peak, As Linked to Cortical Neurodegeneration, Ovarian Estrogen Receptor Alpha, and Melatonin Receptor 2.

Abdelmissih S, Hosny S, Elwi H, Sayed W, Eshra M, Shaker O Psychopharmacology (Berl). 2024; 241(10):2073-2101.

PMID: 38842700 PMC: 11442587. DOI: 10.1007/s00213-024-06619-4.

Identification of Gene Expression in Different Stages of Breast Cancer with Machine Learning.

Abidalkareem A, Ibrahim A, Abd M, Rehman O, Zhuang H Cancers (Basel). 2024; 16(10).

PMID: 38791943 PMC: 11120052. DOI: 10.3390/cancers16101864.

Adenosine receptors in breast cancer.

Mahdizadeh M, Heydari N, Shafiei A, Akbari H, Jafari S Mol Biol Rep. 2024; 51(1):464.

PMID: 38551734 DOI: 10.1007/s11033-024-09382-z.

Molecular docking analysis of triterpenoids from with breast cancer targets.

Christopher I, Sounderraajan A, Murugesan V, Sabapathy I, Periyasamy V, Manikkam R Bioinformation. 2023; 19(11):1067-1074.

PMID: 38046519 PMC: 10692988. DOI: 10.6026/973206300191067.

Regulation of Hypoxic-Adenosinergic Signaling by Estrogen: Implications for Microvascular Injury.

Cassavaugh J, Qureshi N, Csizmadia E, Longhi M, Matyal R, Robson S Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986520 PMC: 10059944. DOI: 10.3390/ph16030422.

References

Borea P, Varani K, Vincenzi F, Baraldi P, Aghazadeh Tabrizi M, Merighi S . The A3 adenosine receptor: history and perspectives. Pharmacol Rev. 2014; 67(1):74-102. DOI: 10.1124/pr.113.008540. View

Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362(9382):419-27. DOI: 10.1016/s0140-6736(03)14065-2. View

Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi P . A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther. 2003; 100(1):31-48. DOI: 10.1016/s0163-7258(03)00084-6. View

Chen J, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D . A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci. 1999; 19(21):9192-200. PMC: 6782932. View

Vonderhaar B . Regulation of development of the normal mammary gland by hormones and growth factors. Cancer Treat Res. 1988; 40:251-66. DOI: 10.1007/978-1-4613-1733-3_12. View

. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

Sullivan J . Estrogen replacement therapy. Am J Med. 1996; 101(4A):4A56S-59S; discussion 59S-60S. DOI: 10.1016/s0002-9343(96)00321-x. View

Canals M, Angulo E, Casado V, Canela E, Mallol J, Vinals F . Molecular mechanisms involved in the adenosine A and A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. J Neurochem. 2005; 92(2):337-48. DOI: 10.1111/j.1471-4159.2004.02856.x. View

Fishman P, Bar-Yehuda S, Madi L, Cohn I . A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs. 2002; 13(5):437-43. DOI: 10.1097/00001813-200206000-00001. View

10.

Gessi S, Merighi S, Sacchetto V, Simioni C, Borea P . Adenosine receptors and cancer. Biochim Biophys Acta. 2010; 1808(5):1400-12. DOI: 10.1016/j.bbamem.2010.09.020. View

11.

Synowitz M, Glass R, Farber K, Markovic D, Kronenberg G, Herrmann K . A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res. 2006; 66(17):8550-7. DOI: 10.1158/0008-5472.CAN-06-0365. View

12.

Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R . Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000; 283(4):485-91. DOI: 10.1001/jama.283.4.485. View

13.

Sachdeva S, Gupta M . Adenosine and its receptors as therapeutic targets: An overview. Saudi Pharm J. 2013; 21(3):245-53. PMC: 3744929. DOI: 10.1016/j.jsps.2012.05.011. View

14.

Yasuda Y, Saito M, Yamamura T, Yaguchi T, Nishizaki T . Extracellular adenosine induces apoptosis in Caco-2 human colonic cancer cells by activating caspase-9/-3 via A(2a) adenosine receptors. J Gastroenterol. 2009; 44(1):56-65. DOI: 10.1007/s00535-008-2273-7. View

15.

Christofi F, Zhang H, Yu J, Guzman J, Xue J, Kim M . Differential gene expression of adenosine A1, A2a, A2b, and A3 receptors in the human enteric nervous system. J Comp Neurol. 2001; 439(1):46-64. DOI: 10.1002/cne.1334. View

16.

Burnstock G . Purinergic signalling. Br J Pharmacol. 2006; 147 Suppl 1:S172-81. PMC: 1760723. DOI: 10.1038/sj.bjp.0706429. View

17.

Panjehpour M, Karami-Tehrani F . Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res. 2008; 16(12):575-85. DOI: 10.3727/000000007783629981. View

18.

Etique N, Grillier-Vuissoz I, Lecomte J, Flament S . Crosstalk between adenosine receptor (A2A isoform) and ERalpha mediates ethanol action in MCF-7 breast cancer cells. Oncol Rep. 2009; 21(4):977-81. DOI: 10.3892/or_00000311. View

19.

Frasor J, Danes J, Komm B, Chang K, Lyttle C, Katzenellenbogen B . Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 2003; 144(10):4562-74. DOI: 10.1210/en.2003-0567. View

20.

Gao Z, Li B, Day Y, Linden J . A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol. 2000; 59(1):76-82. DOI: 10.1124/mol.59.1.76. View